Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity

Cancer Research

Volumn 67, Issue 16, 2007, Pages 7798-7806

  Mukhopadhaya, Arunika ^a   Mendecki, Joseph ^a   Dong, Xinyuan ^a   Liu, Laibin ^a   Kalnicki, Shalom ^a   Garg, Madhur ^a   Alfieri, Alan ^a   Guha, Chandan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; LIPOCORTIN 5; TUMOR ANTIGEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL MATURATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HELPER CELL; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; NECROSIS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34548012362     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0203     Document Type: Article

References (50)

1. Vicini FA, Horwitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol 1997;158:319-25.
2. Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;37:1059-65.
3. Hurwitz MD, Kaplan ID, Svensson GK, Hynynen K, Hansen MS. Feasibility and patient tolerance of a novel transrectal ultrasound hyperthermia system for treatment of prostate cancer. Int J Hyperthermia 2001;17:31-7.
4. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:535-49.
5. Li WX, Franklin WA. Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells. Radiat Res 1998;150:190-4.
6. Milani V, Noessner E, Ghose S, et al. Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia 2002;18:563-75.
7. Shi H, Cao T, Connolly JE, et al. J. Hyperthermia enhances CTL cross-priming. J Immunol 2006;176:2134-41.
8. Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs 2005;6:592-6.
9. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination withirradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
10. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829-33.
11. Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-5.
12. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-6.
13. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
14. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients withmetastatic melanoma. J Clin Oncol 2003;21:3343-50.
15. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-30.
16. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46:82-7.
17. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006;6:1163-7.
18. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients withmetastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
19. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients withmetastatic cancer. Cancer 2000;89:2646-54.
20. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59:4035-41.
21. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients withme tastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999-1010.
22. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61:2062-70.
23. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30.
24. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-13.
25. Inaba K, Swiggard WJ, Steinman R, Romani N, Schuler G. Isolation of Dendritic cells. Hoboken (NJ): Wiley Interscience; 2006. p. Unit 3.7.
26. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
27. Kawakita M, Rao GS, Ritchey JK, et al. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst 1997;89:428-36.
28. Griffith TS, Kawakita M, Tian J, et al. Inhibition of murine prostate tumor growthand activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 2001;93:998-1007.
29. Yonezawa M, Otsuka T, Matsui N, et al. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer 1996;66:347-51.
30. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
31. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
32. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-7.
33. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell deathreleases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κ B pathway. Int Immunol 2000;12:1539-46.
34. Larmonier N, Merino D, Nicolas A, et al. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis 2006;11:1513-24.
35. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105-9.
36. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33.
37. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999;29:1617-25.
38. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction withapoptoti c tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000;60:2209-17.
39. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8:657-65.
40. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-13.
41. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42.
42. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK. Heat shock protein vaccines against cancer. J Immunother 1993;14:352-6.
43. Lewis JJ. Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14653-6.
44. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006;18:201-5.
45. Alfieri AA, Hahn EW, Kim JH. Role of cell-mediated immunity in tumor eradication by hyperthermia. Cancer Res 1981;41:1301-5.
46. Chakravarty PK, Guha C, Alfieri A, et al. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. Oncology 2006;70:245-4.
47. Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999;59:6028-32.
48. Corica FA, Cheng L, Ramnani D, et al. Transurethral hot-water balloon thermoablation for benign prostatic hyperplasia: patient tolerance and pathologic findings. Urology 2000;56:76-80.
49. Djavan B, Susani M, Shariat S, et al. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. Tech Urol 1998;4:103-9.
50. Sanghvi NT, Foster RS, Bihrle R, et al. Noninvasive surgery of prostate tissue by high intensity focused ultrasound: an updated report. Eur J Ultrasound 1999;9:19-29.